We may earn commissions if you use the recommended services on this site.  

Moderna's Phase Three Trial Shows Promising Results for Flu Vaccine, Clearing Path to Approval

Latest Business News

Moderna's Experimental Flu Vaccine Shows Promising Results in Late-Stage Trial

Moderna announced on Wednesday that its experimental mRNA-based flu vaccine demonstrated a stronger immune response against four strains of the virus compared to the currently available flu vaccine in a late-stage trial. This breakthrough paves the way for potential approval in the United States. Following the announcement, Moderna's shares rose by 4% in premarket trading.

Expanding Moderna's Pipeline

These results are significant as Moderna aims to diversify its product portfolio beyond its highly successful mRNA COVID-19 vaccine. With recent approvals from U.S. regulators for its COVID-19 vaccine, Moderna expects its COVID shot, along with its flu jab and other experimental respiratory vaccines, to generate up to $15 billion in sales by 2027.

Relief for Moderna

The positive results from the late-stage trial come as a relief for Moderna after the delay of its experimental flu shot program in April. The initial vaccine formula did not gather sufficient data to determine its efficacy, prompting the company to reformulate the shot. The efforts paid off in the latest phase three trial, where Moderna's flu vaccine, known as mRNA-1010, outperformed the currently approved seasonal flu vaccine, Fluarix, from GlaxoSmithKline. The interim analysis revealed higher antibody levels for all four influenza strains recommended by the World Health Organization.

Focus on Safety and Efficacy

Moderna reported that the safety findings in the trial were consistent with previous studies, with common side effects including muscle pain, headache, fatigue, and pain and swelling at the injection site. Additionally, Moderna announced the discontinuation of a separate phase three trial for the first version of its flu vaccine, citing insufficient data to determine efficacy.

Future Prospects and Respiratory Disease Programs

Moderna also shared its expectations for a decision from the Food and Drug Administration (FDA) on its mRNA vaccine for respiratory syncytial virus (RSV) in adults aged 60 and older by April. The FDA previously approved RSV vaccines for older adults from Pfizer and GSK in May. Moderna's CEO, Stephane Bancel, expressed confidence in the company's mRNA platform and highlighted the positive phase three data across respiratory disease programs. In conclusion, Moderna's experimental flu vaccine has shown promising results in a late-stage trial, bolstering the company's efforts to expand its product offerings beyond the COVID-19 vaccine. The positive outcomes and ongoing advancements in respiratory disease programs demonstrate Moderna's commitment to addressing critical healthcare needs.

Conclusion: Implications of Moderna's Experimental Flu Vaccine for New Businesses

The promising results of Moderna's experimental flu vaccine in a late-stage trial present several implications for new businesses, particularly in the healthcare sector.

Opportunities in Vaccine Development

Moderna's success underscores the potential for innovation in vaccine development, especially with mRNA technology. This opens up opportunities for new businesses to explore this field and contribute to addressing critical health concerns.

Importance of Diversification

Moderna's efforts to diversify its product portfolio beyond its COVID-19 vaccine highlight the importance of diversification for business sustainability. New businesses can take a cue from this and strive to diversify their offerings to ensure long-term success.

Adapting to Challenges

The challenges Moderna faced in the development of its flu vaccine, and its subsequent success, underline the importance of adaptability and resilience in business. New businesses must be prepared to face and overcome obstacles in their journey.

Impact on Healthcare Industry

Moderna's advancements in respiratory disease programs could potentially reshape the healthcare industry, creating new opportunities and challenges for businesses in this sector. In conclusion, Moderna's experimental flu vaccine's promising results have significant implications for new businesses. By seizing opportunities in vaccine development, diversifying offerings, adapting to challenges, and staying abreast of industry developments, new businesses can navigate their path to success.
Story First Published at: https://www.cnbc.com/2023/09/13/moderna-flu-vaccine-shows-promising-phase-three-trial-results.html
Brought to you by BusinessFormation.io
Know Your State's Registered Agent Requirements: What is a Registered Agent
Learn How To Create An LLC: What Is An LLC and How To Start an LLC Online

LLC Filing & Registered Agent Services

Compare Online LLC Filing Services Today

We work with the market leaders in business formation and registered agent services.

Getting started is simple and inexpensive. Form your business today & secure your brand name before someone beats you to it! Click below to view the Top 3 Best LLC and registered agent service providers.
View Top 3 Providers Now

Filing An LLC Can Be Complicated

Streamline Your LLC Filing Online for $39

Northwest Registered Agent is the best-rated service for first time filers.

Get professional LLC formation & registered agent services for only $39 + state filing fee. This offers includes your full LLC setup, plus a private business address, lifetime support, and more.

Trusted by Millions. Save 82% Today.